etiocholanolone has been researched along with istaroxime in 46 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 22 (47.83) | 29.6817 |
| 2010's | 15 (32.61) | 24.3611 |
| 2020's | 9 (19.57) | 2.80 |
| Authors | Studies |
|---|---|
| Bianchi, G; Carminati, P; De Munari, S; Ferrari, P; Gagnol, RJ; Loi, MF; Mattera, GG; Melloni, P; Micheletti, R; Rocchetti, M; Schiavone, A; Zaza, A | 1 |
| Besana, A; Ferrari, P; Micheletti, R; Mostacciuolo, G; Rocchetti, M; Zaza, A | 1 |
| Adamson, PB; Carminati, P; Gagnol, JP; Germany, R; Mattera, GG; Schwartz, PJ; Vanoli, E | 1 |
| Almirante, N; Banfi, L; Carzana, G; Cerri, A; De Munari, S; Ferrari, P; Gobbini, M; Marazzi, G; Melloni, P; Micheletti, R; Schiavone, A; Sputore, S; Torri, M; Zappavigna, MP | 1 |
| Besana, A; Ferrari, P; Jona, I; Micheletti, R; Mostacciuolo, G; Rocchetti, M; Sarkozi, S; Szegedi, C; Zaza, A | 1 |
| Ashley, EA; deGoma, EM; Fowler, MB; Vagelos, RH | 1 |
| Gheorghiade, M; Sabbah, HN | 1 |
| Barassi, P; Bianchi, G; Ferrandi, M; Ferrari, P; Giacalone, G; Micheletti, R; Moro, B; Palazzo, F; Parodi, O; Schiavone, A | 1 |
| Borsini, F; Carminati, P; Gagnol, JP; Lo Giudice, P; Loi, FM; Mattera, GG; Vanoli, E | 1 |
| Amato, A; Carminati, P; Cowart, D; Gheorghiade, M; Imai, M; Sabbah, HN | 1 |
| Amato, A; Carminati, P; Cowart, D; Ghali, JK; Gheorghiade, M; Haynos, W; Rayburn, BK; Smith, WB; Torre-Amione, G; Valentini, G; Zhang, D | 1 |
| Wehrens, XH | 1 |
| Bilińska, ZT; Skóra, E | 1 |
| Böhm, M; De Luca, L; Dickstein, K; El-Banayosy, A; Filippatos, G; Gheorghiade, M; Mebazaa, A; Nieminen, M; Parissis, JT; Rhodes, A; Voors, AA; Zannad, F | 1 |
| Bianchetti, M; Blair, JE; Bubenek-Turconi, SI; Carminati, P; Ceracchi, M; Filippatos, GS; Gheorghiade, M; Korewicki, J; Kremastinos, D; Macarie, C; Ruzyllo, W; Sabbah, HN; Valentini, G | 1 |
| Dec, GW | 1 |
| Alemanni, M; Altomare, C; Barassi, P; Chisci, R; Ferrari, P; Micheletti, R; Mostacciuolo, G; Rocchetti, M; Zaza, A | 1 |
| Armaroli, S; Banfi, L; Benicchio, A; Carzana, G; Cerri, A; Fedrizzi, G; Ferrari, P; Giacalone, G; Giubileo, M; Gobbini, M; Marazzi, G; Micheletti, R; Moro, B; Pozzi, M; Scotti, PE; Torri, M | 1 |
| Borsini, F; Carminati, P; Gagnol, JP; Loi, FM; Mattera, GG; Vanoli, E | 1 |
| Blair, JE; Filippatos, GS; Gheorghiade, M; Harinstein, ME; Khan, H; Metra, M; Porchet, H; Sabbah, HN; Valentini, G; Vogel, M | 1 |
| Bianchetti, M; Blair, JE; Bubenek-Turconi, SI; Carminati, P; Ceracchi, M; Filippatos, GS; Gheorghiade, M; Grzybowski, J; Korewicki, J; Kremastinos, D; Macarie, C; Ruzyllo, W; Sabbah, HN; Shah, SJ; Valentini, G | 1 |
| Cas, LD; Cotter, G; Gheorghiade, M; Metra, M; Sabbah, HN; Teerlink, JR; Zacà, V | 1 |
| Armaroli, S; Banfi, L; Benicchio, A; Carzana, G; Cerri, A; Ferrari, P; Giacalone, G; Gobbini, M; Marazzi, G; Micheletti, R; Moro, B; Sputore, S; Torri, M; Zappavigna, MP | 1 |
| Hullin, R; Keller, RF; Lerch, R; Meyer, P; White, M | 1 |
| Campia, U; Gheorghiade, M; Nodari, S | 1 |
| Borsini, F; Gagnol, JP; Lo Giudice, P; Mattera, GG | 1 |
| Alemanni, M; Re, D; Rocchetti, M; Zaza, A | 1 |
| Hoffman, TM | 1 |
| Farmakis, D; Filippatos, G | 1 |
| Fevre, M; Leroux, JC; Luciani, P | 1 |
| Ambrosy, AP; Ferrandi, M; Ferrari, P; Gheorghiade, M | 1 |
| Barassi, P; Bartolommei, G; Bianchi, G; Ferrandi, M; Ferrari, P; Molinari, I; Moncelli, MR; Reina, C; Tadini-Buoninsegni, F; Tripodi, MG | 1 |
| Antoons, G; Biesmans, L; Heinzel, FR; Herchuelz, A; Hohendanner, F; Ljubojević, S; MacQuaide, N; Pieske, B; Platzer, D; Sacherer, M; Sedej, S; Sipido, K; Sokolow, S; Wakula, P | 1 |
| Ahmad, A; Ahmad, S; Chandler, JD; Claycomb, WC; Day, BJ; Hendry-Hofer, TB; Loader, JE; Mozziconacci, O; Powell, RL; Reisdorph, N; Schöneich, C; Veress, LA; White, CW | 1 |
| Alarifi, S; Alevizopoulos, K; Alkahtani, S; Calogeropoulou, T; Dimas, K; Honisch, S; Lang, F; Papadopoulou, N; Prousis, KC; Schmidt, EM; Stournaras, C; Tsapara, A | 1 |
| Curcic, P; Eaton, DM; Khafaga, M; Knez, I; Kolesnik, E; Köstenberger, M; Lewinski, DV; Pichler, M; Pieske, B; Rainer, PP; Schwantzer, G; Vafiadis, A; Wallner, M | 1 |
| Al-Maghout, T; Alevizopoulos, K; Alkahtani, S; Bochem, J; Calogeropoulou, T; Dimas, K; Kallergi, G; Lang, F; Pelzl, L; Schmid, E; Stagno, MJ; Stournaras, C; Tsapara, A; Warmann, SW; Zacharopoulou, N | 1 |
| Butler, J; Chioncel, O; Collins, SP | 1 |
| Altomare, C; Arici, M; Barassi, P; Bianchi, G; Boz, E; Bussadori, C; Chang, GJ; Ferrandi, M; Ferrari, P; Hsu, SC; Lodrini, AM; Mostacciuolo, G; Rocchetti, M; Sala, E; Torre, E; Vagni, S | 1 |
| Bakkers, J; Boukens, BJD; Chocron, S; de Boer, TP; de Jonge, B; Kamel, SM; Koopman, CD; Onderwater, YL; Polidoro Pontalti, C; van Alebeek, E; van Opbergen, CJM; van Veen, TAB; Verkerk, AO; Vos, MA; Weuring, WJ | 1 |
| Cornelius, F; Kanai, R; Toyoshima, C; Vilsen, B | 1 |
| Chioncel, O; Cotter, G; Davison, B; Filippatos, G; Mebazaa, A; Metra, M; Novosadova, M; Ponikowski, P; Simmons, P; Simonson, S; Soffer, J | 1 |
| Avvisato, R; Jankauskas, SS; Santulli, G | 1 |
| Adamo, M; Chioncel, O; Cotter, G; Davison, B; Filippatos, G; Mebazaa, A; Metra, M; Novosadova, M; Pagnesi, M; Ponikowski, P; Simmons, P; Simonson, S; Soffer, J | 1 |
| Silverman, DN; Tedford, RJ | 1 |
| Canturk, P; Gok, E; Gungor, B; Karakus, G; Katin, KP; Kaya, S; Unal, N | 1 |
9 review(s) available for etiocholanolone and istaroxime
| Article | Year |
|---|---|
Emerging therapies for the management of decompensated heart failure: from bench to bedside.
Topics: Antidiuretic Hormone Receptor Antagonists; Atrial Natriuretic Factor; Cardiac Myosins; Cardiotonic Agents; Cardiovascular Agents; Etiocholanolone; Heart Failure; Humans; Natriuretic Agents; Peptide Fragments; Perhexiline; Purinergic P1 Receptor Antagonists; Sodium-Potassium-Exchanging ATPase | 2006 |
Istaroxime, a novel luso-inotropic agent for the treatment of acute heart failure.
Topics: Acute Disease; Animals; Cardiotonic Agents; Enzyme Inhibitors; Etiocholanolone; Heart Failure; Humans; Molecular Structure; Patents as Topic; Sodium-Potassium-Exchanging ATPase; Structure-Activity Relationship; Treatment Outcome | 2007 |
[New therapeutic goals--new drugs in heart failure treatment].
Topics: Amides; Cardiovascular Agents; Etiocholanolone; Fumarates; Heart Failure; Humans; Neovascularization, Physiologic; Ventricular Remodeling | 2007 |
Overview of emerging pharmacologic agents for acute heart failure syndromes.
Topics: Adenosine; Cardiovascular Agents; Endothelin-1; Etiocholanolone; Heart Failure; Hemodynamics; Humans; Hydrazones; Natriuretic Peptide, Brain; Perhexiline; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Sodium-Potassium-Exchanging ATPase; Syndrome; Vasodilator Agents | 2008 |
Istaroxime, a first in class new chemical entity exhibiting SERCA-2 activation and Na-K-ATPase inhibition: a new promising treatment for acute heart failure syndromes?
Topics: Acute Disease; Animals; Cardiotonic Agents; Dobutamine; Etiocholanolone; Heart Failure; Hemodynamics; Humans; Pulmonary Wedge Pressure; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Sodium-Potassium-Exchanging ATPase | 2009 |
Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond.
Topics: Acute Disease; Cardiotonic Agents; Digoxin; Dobutamine; Etiocholanolone; Exercise Test; Heart Failure; Hemodynamics; Hospitals, Group Practice; Humans; Hydrazones; Prognosis; Pyrazines; Pyridazines; Quinolines; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Simendan; Treatment Outcome; Urea; Vasodilator Agents | 2009 |
[What is new in the medical management of acute heart failure?].
Topics: Acute Disease; Adenosine; Algorithms; Cardiotonic Agents; Diuretics; Drug Therapy, Combination; Etiocholanolone; Heart Failure; Hemodiafiltration; Humans; Oxygen Inhalation Therapy; Practice Guidelines as Topic; Prognosis; Relaxin; Risk Factors; Treatment Outcome; Vasoconstrictor Agents; Vasodilator Agents; Vasopressins | 2010 |
Newer inotropes in pediatric heart failure.
Topics: Cardiotonic Agents; Child; Clinical Trials as Topic; Drug Administration Schedule; Etiocholanolone; Heart Failure; Humans; Hydrazones; Milrinone; Myocardial Contraction; Pyridazines; Simendan; Treatment Outcome | 2011 |
Combining SERCA2a activation and Na-K ATPase inhibition: a promising new approach to managing acute heart failure syndromes with low cardiac output.
Topics: Animals; Cardiac Output, Low; Etiocholanolone; Heart Failure; Humans; Models, Biological; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Sodium-Potassium-Exchanging ATPase | 2011 |
5 trial(s) available for etiocholanolone and istaroxime
| Article | Year |
|---|---|
A phase 1-2 dose-escalating study evaluating the safety and tolerability of istaroxime and specific effects on electrocardiographic and hemodynamic parameters in patients with chronic heart failure with reduced systolic function.
Topics: Adult; Aged; Blood Pressure; Cardiography, Impedance; Cardiotonic Agents; Dose-Response Relationship, Drug; Etiocholanolone; Female; Half-Life; Heart Failure; Heart Rate; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Contraction | 2007 |
Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Cardiotonic Agents; Diastole; Etiocholanolone; Female; Heart Failure; Heart Rate; Hemodynamics; Hospitalization; Humans; Infusions, Intravenous; Male; Middle Aged; Sodium-Potassium-Exchanging ATPase; Stroke Volume; Systole; Ultrasonography | 2008 |
Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: results from the Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: a Randomized Controlled Trial in P
Topics: Acute Disease; Aged; Cardiovascular Agents; Diastole; Etiocholanolone; Female; Heart; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Sodium-Potassium-Exchanging ATPase; Stroke Volume | 2009 |
Safety and efficacy of istaroxime in patients with acute heart failure-related pre-cardiogenic shock - a multicentre, randomized, double-blind, placebo-controlled, parallel group study (SEISMiC).
Topics: Cardiotonic Agents; Double-Blind Method; Etiocholanolone; Heart Failure; Humans; Shock, Cardiogenic | 2022 |
Safety and Efficacy of Istaroxime 1.0 and 1.5 µg/kg/min for Patients With Pre-Cardiogenic Shock.
Topics: Double-Blind Method; Etiocholanolone; Heart; Heart Failure; Humans; Shock, Cardiogenic | 2023 |
32 other study(ies) available for etiocholanolone and istaroxime
| Article | Year |
|---|---|
Pharmacological profile of the novel inotropic agent (E,Z)-3-((2-aminoethoxy)imino)androstane-6,17-dione hydrochloride (PST2744).
Topics: Animals; Cardiotonic Agents; Digoxin; Dogs; Dose-Response Relationship, Drug; Etiocholanolone; Guinea Pigs; Heart Atria; In Vitro Techniques; Myocardial Contraction; Myocardial Infarction; Myocardium; Physical Exertion; Radioligand Assay; Sodium-Potassium-Exchanging ATPase; Ventricular Function, Left | 2002 |
Diverse toxicity associated with cardiac Na+/K+ pump inhibition: evaluation of electrophysiological mechanisms.
Topics: Animals; Arrhythmias, Cardiac; Calcium Channels; Cardiotonic Agents; Cell Separation; Digoxin; Dose-Response Relationship, Drug; Electrophysiology; Enzyme Inhibitors; Etiocholanolone; Female; Guinea Pigs; Heart Diseases; In Vitro Techniques; Membrane Potentials; Myocardium; Potassium Channels, Inwardly Rectifying; Sodium-Potassium-Exchanging ATPase | 2003 |
Hemodynamic effects of a new inotropic compound, PST-2744, in dogs with chronic ischemic heart failure.
Topics: Animals; Cardiotonic Agents; Dobutamine; Dogs; Etiocholanolone; Heart Failure; Hemodynamics; Ventricular Dysfunction, Left | 2003 |
Structure-based design and synthesis of novel potent Na+,K+ -ATPase inhibitors derived from a 5alpha,14alpha-androstane scaffold as positive inotropic compounds.
Topics: Androstanes; Animals; Arrhythmias, Cardiac; Dogs; Enzyme Inhibitors; Etiocholanolone; Guinea Pigs; Models, Molecular; Myocardial Contraction; Sodium-Potassium-Exchanging ATPase; Stereoisomerism; Stimulation, Chemical; Structure-Activity Relationship | 2003 |
Modulation of sarcoplasmic reticulum function by Na+/K+ pump inhibitors with different toxicity: digoxin and PST2744 [(E,Z)-3-((2-aminoethoxy)imino)androstane-6,17-dione hydrochloride].
Topics: Animals; Calcium; Calcium-Transporting ATPases; Digoxin; Electrophysiology; Enzyme Inhibitors; Etiocholanolone; Guinea Pigs; Heart Ventricles; In Vitro Techniques; Membrane Potentials; Myocardial Contraction; Myocytes, Cardiac; Sarcoplasmic Reticulum; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Sodium-Potassium-Exchanging ATPase | 2005 |
Istaroxime: an investigational luso-inotropic agent for acute heart failure syndromes.
Topics: Aged; Cardiotonic Agents; Etiocholanolone; Female; Heart Failure; Humans; Male | 2007 |
Istaroxime, a stimulator of sarcoplasmic reticulum calcium adenosine triphosphatase isoform 2a activity, as a novel therapeutic approach to heart failure.
Topics: Animals; Cardiotonic Agents; Enzyme Activation; Etiocholanolone; Guinea Pigs; Heart Failure; Humans; Muscle, Smooth, Vascular; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Sodium-Potassium-Exchanging ATPase | 2007 |
Istaroxime: a new luso-inotropic agent for heart failure.
Topics: Animals; Blood Pressure; Cricetinae; Dogs; Etiocholanolone; Heart Failure; Heart Rate; Male; Sodium-Potassium-Exchanging ATPase | 2007 |
Hemodynamic properties of a new-generation positive luso-inotropic agent for the acute treatment of advanced heart failure.
Topics: Animals; Blood Pressure; Cardiotonic Agents; Dogs; Echocardiography, Doppler; Electrocardiography; Etiocholanolone; Heart Failure; Heart Rate; Ventricular Function, Left | 2007 |
Istaroxime in heart failure new hope or more hype.
Topics: Acute Disease; Cardiotonic Agents; Etiocholanolone; Heart Failure; Heart Rate; Humans; Stroke Volume | 2008 |
Modulation of sarcoplasmic reticulum function by PST2744 [istaroxime; (E,Z)-3-((2-aminoethoxy)imino) androstane-6,17-dione hydrochloride)] in a pressure-overload heart failure model.
Topics: Animals; Disease Models, Animal; Etiocholanolone; Guinea Pigs; Heart Failure; Myocytes, Cardiac; Sarcoplasmic Reticulum; Sodium-Potassium-Exchanging ATPase | 2008 |
Novel analogues of istaroxime, a potent inhibitor of Na+,K+-ATPase: synthesis and structure-activity relationship.
Topics: Amines; Animals; Etiocholanolone; Guinea Pigs; Hydroxylation; Models, Molecular; Molecular Structure; Sodium-Potassium-Exchanging ATPase; Stereoisomerism; Structure-Activity Relationship | 2008 |
Sympathomimetic inefficiency in restoring contractility in the acute or chronic beta-blocker-treated ischaemic heart: comparison with a new agent.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Cardiotonic Agents; Dobutamine; Dogs; Etiocholanolone; Male; Milrinone; Myocardial Contraction; Myocardial Infarction; Myocardial Ischemia; Sodium-Potassium-Exchanging ATPase; Sympathomimetics; Time Factors; Treatment Failure; Ventricular Dysfunction, Left | 2008 |
Novel analogues of Istaroxime, a potent inhibitor of Na(+),K(+)-ATPase: Synthesis, structure-activity relationship and 3D-quantitative structure-activity relationship of derivatives at position 6 on the androstane scaffold.
Topics: Androstanes; Animals; Enzyme Inhibitors; Etiocholanolone; Guinea Pigs; Heart Failure; Sodium-Potassium-Exchanging ATPase; Stereoisomerism; Structure-Activity Relationship | 2010 |
Acute heart failure with low cardiac output: can we develop a short-term inotropic agent that does not increase adverse events?
Topics: Acute Disease; Animals; Cardiac Output; Cardiotonic Agents; Clinical Trials as Topic; Digoxin; Dobutamine; Etiocholanolone; Genetic Therapy; Heart Failure; Humans; Hydrazones; Pyridazines; Ryanodine Receptor Calcium Release Channel; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Simendan; Sodium-Potassium-Exchanging ATPase; Urea | 2010 |
Chronic istaroxime improves cardiac function and heart rate variability in cardiomyopathic hamsters.
Topics: Animals; Autonomic Agents; Cardiomyopathies; Cardiotonic Agents; Cricetinae; Etiocholanolone; Heart; Heart Rate; Male; Myocardial Contraction; Myocardium; Organ Size; Protective Agents; Sodium-Potassium-Exchanging ATPase; Time Factors | 2011 |
Role and mechanism of subcellular Ca2+ distribution in the action of two inotropic agents with different toxicity.
Topics: Animals; Calcium; Cardiotonic Agents; Cells, Cultured; Digoxin; Electrophysiology; Etiocholanolone; Female; Mice; Mice, Inbred C57BL; Sarcoplasmic Reticulum; Sodium-Potassium-Exchanging ATPase | 2011 |
Istaroxime: is the remedy better than the disease?: Editorial to: "Chronic istaroxine improves cardiac function and heart rate variability in cardiomyopathic hamsters" by Pietro Lo Giudice et al.
Topics: Animals; Cardiomyopathies; Cardiotonic Agents; Etiocholanolone; Heart; Heart Rate; Male | 2011 |
Development and physico-chemical characterization of a liposomal formulation of istaroxime.
Topics: Chemistry, Pharmaceutical; Drug Delivery Systems; Etiocholanolone; Excipients; Kinetics; Liposomes; Phosphatidylcholines; Polyethylene Glycols; Proton-Motive Force; Temperature | 2011 |
Istaroxime stimulates SERCA2a and accelerates calcium cycling in heart failure by relieving phospholamban inhibition.
Topics: Animals; Calcium; Calcium-Binding Proteins; Dogs; Etiocholanolone; Guinea Pigs; Heart Failure; Humans; In Vitro Techniques; Male; Microsomes; Rabbits; Sarcoplasmic Reticulum; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Spodoptera | 2013 |
Intracellular dyssynchrony of diastolic cytosolic [Ca²⁺] decay in ventricular cardiomyocytes in cardiac remodeling and human heart failure.
Topics: Aniline Compounds; Animals; Calcium Signaling; Calcium-Transporting ATPases; Colforsin; Cytosol; Diastole; Electric Stimulation; Etiocholanolone; Heart Failure; Heart Ventricles; Humans; Hypertrophy; Hypertrophy, Left Ventricular; Indoles; Mice; Mitochondria, Heart; Myocardial Ischemia; Myocytes, Cardiac; Phenyl Ethers; Ruthenium Compounds; Sarcomeres; Sarcoplasmic Reticulum; Sodium-Calcium Exchanger; Sus scrofa; Swine; Ventricular Remodeling | 2013 |
Sarcoendoplasmic reticulum Ca(2+) ATPase. A critical target in chlorine inhalation-induced cardiotoxicity.
Topics: Adenosine Triphosphate; Animals; Antioxidants; Apoptosis; Calcium Signaling; Cardiotonic Agents; Cells, Cultured; Chlorine; Etiocholanolone; Heart Diseases; Inhalation Exposure; Male; Mitochondria, Heart; Myocardium; Myocytes, Cardiac; Ranolazine; Rats, Sprague-Dawley; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Thiocyanates | 2015 |
Functional characterization and anti-cancer action of the clinical phase II cardiac Na+/K+ ATPase inhibitor istaroxime: in vitro and in vivo properties and cross talk with the membrane androgen receptor.
Topics: Animals; Apoptosis; Cell Line; Cell Line, Tumor; Cell Proliferation; Clinical Trials, Phase II as Topic; Etiocholanolone; Female; HCT116 Cells; Humans; Male; MCF-7 Cells; Mice, Inbred NOD; Mice, SCID; Prostatic Neoplasms; Protein Binding; Receptors, Androgen; Sodium-Potassium-Exchanging ATPase; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Istaroxime, a potential anticancer drug in prostate cancer, exerts beneficial functional effects in healthy and diseased human myocardium.
Topics: Antineoplastic Agents; Cardiotonic Agents; Dose-Response Relationship, Drug; Etiocholanolone; Heart; Heart Atria; Heart Failure; Heart Ventricles; Humans; Strophanthidin | 2017 |
Istaroxime Inhibits Motility and Down-Regulates Orai1 Expression, SOCE and FAK Phosphorylation in Prostate Cancer Cells.
Topics: Calcium; Calcium Channels; Cell Line, Tumor; Cell Movement; Epithelial Cells; Etiocholanolone; Fluorescent Dyes; Focal Adhesion Kinase 1; Fura-2; Gene Expression Regulation, Neoplastic; Humans; Male; Neoplasm Proteins; ORAI1 Protein; Phosphorylation; Prostate; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction; Sodium Channel Blockers; Stromal Interaction Molecule 1; Sulfonamides | 2017 |
Istaroxime in acute heart failure: the holy grail is at HORIZON?
Topics: Cardiotonic Agents; Etiocholanolone; Heart Failure; Humans | 2020 |
SERCA2a stimulation by istaroxime improves intracellular Ca2+ handling and diastolic dysfunction in a model of diabetic cardiomyopathy.
Topics: Animals; Calcium; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Etiocholanolone; Rats; Sarcoplasmic Reticulum; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Sodium-Potassium-Exchanging ATPase | 2022 |
Istaroxime treatment ameliorates calcium dysregulation in a zebrafish model of phospholamban R14del cardiomyopathy.
Topics: Animals; Calcium; Calcium-Binding Proteins; Cardiomyopathy, Dilated; Disease Models, Animal; Echocardiography; Etiocholanolone; Female; Gene Knock-In Techniques; Humans; Male; Myocardial Contraction; Myocardium; Sequence Deletion; Zebrafish | 2021 |
Cryoelectron microscopy of Na
Topics: Adenosine Triphosphate; Cardiac Glycosides; Cardiotonic Agents; Cations; Cryoelectron Microscopy; Etiocholanolone; Magnesium; Ouabain; Protein Domains; Sodium; Sodium-Potassium-Exchanging ATPase | 2022 |
Istaroxime and Beyond: New Therapeutic Strategies to Specifically Activate SERCA and Treat Heart Failure.
Topics: Cardiotonic Agents; Etiocholanolone; Heart Failure; Humans; Sarcoplasmic Reticulum Calcium-Transporting ATPases | 2023 |
Istaroxime in HFpEF: Can We Relax Already?
Topics: Cardiotonic Agents; Etiocholanolone; Heart Failure; Humans; Stroke Volume | 2023 |
Evaluation of the Anticancer and Biological Activities of Istaroxime via Ex Vivo Analyses, Molecular Docking and Conceptual Density Functional Theory Computations.
Topics: Antineoplastic Agents; Density Functional Theory; Etiocholanolone; Molecular Docking Simulation | 2023 |